Q-omics provides the consensus-scored NEFHP1 profile across patient tissues and cancer cell-line models. NEFHP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, NEFHP1 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, NEFHP1 RNA expression shows 6,518 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, PRAD, and STAD as cancer lineages where NEFHP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEFHP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEFHP1 survival associations across molecular data types. NEFHP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEFHP1 RNA expression–survival associations across cancer types. High NEFHP1 expression shows unfavorable associations in READ, MESO, BLCA, ACC and COAD, but favorable associations in HNSC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for NEFHP1 RNA expression.
This table summarizes NEFHP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for NEFHP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEFHP1 shows lower tumor expression in PRAD and higher tumor expression in LUAD and LUSC. The PRAD box plot shows higher NEFHP1 RNA expression in normal versus tumor tissue (log2 FC = −0.155, t-test p = .012).
This table shows molecular features associated with NEFHP1 in patient tissues and cancer cell lines. In patient samples, NEFHP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
